Trial Profile
A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other Myelodysplastic /Myeloproliferative Neoplasias, and Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Nov 2021
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Therapeutic Use
- Sponsors Kura Oncology
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress
- 12 May 2021 Status changed from active, no longer recruiting to completed.
- 21 Jun 2020 Results (n=34; as of 24 Jan 2020) of preliminary efficacy, safety and biomarker data presented at the 25th Congress of the European Haematology Association